CELL LOCALIZATION SIGNATURE AND IMMUNOTHERAPY

The present disclosure provides methods of identifying a subject suitable for an anti-PD-1/PD-L1 antagonist therapy comprising measuring assay CD8 localization and PD-L1 expression in a tumor sample obtained from the subject. In some aspects, method further comprises administering (i) an anti-PD-1/P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BAXI Vipul A, WOJCIK John B, FISHER Andrew, TRILLO-TINOCO Jimena, CHEN Benjamin J, LEE George C, ELY Scott, GRAY Falon, PANDYA Dimple, COHEN Daniel N, EDWARDS Robin
Format: Patent
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present disclosure provides methods of identifying a subject suitable for an anti-PD-1/PD-L1 antagonist therapy comprising measuring assay CD8 localization and PD-L1 expression in a tumor sample obtained from the subject. In some aspects, method further comprises administering (i) an anti-PD-1/PD-L1 antagonist therapy or (ii) an anti-PD-1/PD-L1 antagonist and anti-CTLA-4 antagonist combination therapy to a subject identified as having a tumor exhibiting an excluded CD8 localization phenotype, wherein the tumor is PD-L1 negative. La presente invención se refiere a métodos para identificar a un sujeto adecuado para una terapia con antagonista anti-PD-1/PD-L1 que comprende medir el ensayo de localización de CD8 y expresión de PD-L1 en una muestra de tumor obtenida a partir del sujeto. En algunos aspectos, el método comprende además administrar (i) una terapia con antagonista anti-PD-1/PD-L1 o (ii) una terapia de combinación con antagonista anti-PD-1/PD-L1 y antagonista anti-CTLA-4 y a un sujeto identificado como que tiene un tumor que presenta un fenotipo de localización de CD8 excluido, en donde el tumor es PD-L1 negativo.